Skip to main content
. 2018 May 2;36(19):1981–1990. doi: 10.1200/JCO.2018.78.0858

Fig 3.

Fig 3.

Disease-free survival (DFS) in (A) the whole study population, (B) patients with estrogen receptor–positive disease, and (C) patients with estrogen receptor–negative disease. GnRHa, gonadotropin-releasing hormone agonists.